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M ethotrexate (MTX) interferes with the metabo-lism of folic acid and blocks the synthesis of 
DNA.  MTX plays an important role in the treatment of 
acute lymphoblastic leukemia (ALL),  both as a prophy-
laxis against and a treatment for central nervous system 
(CNS) involvement,  due to its ability to penetrate the 
brain-blood barrier.  MTX is administered at various 
doses ranging from higher than 500 mg/m2 intrave-
nously to as low as 12 mg intrathecally [1].  While acute 
kidney injury (AKI) can develop as a consequence of the 
precipitation of MTX and its metabolites in the renal 
tubules following the administration of MTX at doses 
exceeding 500 mg/m2,  AKI has rarely been reported at 
lower doses [1-3].
Recent studies have reported that polymorphisms 
within several MTX pathway genes are suspected to 
exacerbate MTX toxicities and increase MTX plasma 
levels [4-6].  Moreover,  genome-wide association stud-
ies (GWAS) have revealed that plasma MTX elimination 
is associated with polymorphisms in the Solute Carrier 
Organic Anion Transporter Family Member 1B1 
(SLCO1B1) gene [7-9].  However,  the clinical signifi-
cance of such polymorphisms remains to be elucidated.
Herein,  we report the case of a pediatric patient 
with ALL who suffered from delayed MTX elimination 
following the intravenous administration of MTX at a 
dose of 150 mg/m2 during maintenance therapy.  We 
analyzed his germline polymorphisms of candidate 
genes for MTX toxicities and clearance,  and deter-
mined that he was a carrier of dysfunctional variants.
Case Report
The patient was a 7-year-old boy who had com-
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Polymorphisms in methotrexate transporter pathways have been associated with methotrexate toxicities and 
clearance.  Recent genome-wide association studies have revealed that the SLCO1B1 T521C variant is associated 
with methotrexate elimination.  We present a case of a pediatric patient with acute lymphoblastic leukemia who 
suffered from persistently high plasma methotrexate concentrations and acute kidney injuries after the admin-
istration of a medium dose of methotrexate.  Subsequent genetic analysis showed that he was a carrier of dys-
functional genetic variants associated with methotrexate clearance.  This case highlights that polymorphisms of 
methotrexate transporter pathways can adversely affect methotrexate elimination in a clinically significant manner.
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plained of fever and lower leg pain for 2 months.  Blood 
examination revealed an elevated white blood cell count 
of 17,000/µl,  platelet count of 71,000/µl,  and lactate 
dehydrogenase of 6,230 U/l.  Bone marrow aspiration 
revealed myeloperoxidase-negative lymphoblasts 
exceeding 90% of all nucleated cells.  Flow cytometry 
analysis of the blasts showed that they were positive for 
CD10,  CD19 and CD79a.  He was diagnosed with B-cell 
precursor ALL (BCP-ALL).  G-band analysis of bone 
marrow cells did not reveal chromosomal abnormali-
ties,  but the TCF3-PBX1 chimeric gene was detected by 
polymerase chain reaction (PCR).  No evidence of CNS 
involvement was found.  The patient received predniso-
lone for 7 days,  but the count of peripheral lympho-
blasts exceeded 1,000/µl on the next day,  demonstrat-
ing his poor response to prednisolone.  The patient was 
enrolled in an extremely high-risk group of the Japan 
Association of Childhood Leukemia Study (JACLS) 
ALL-02 study [10].  The treatment protocol for the 
extremely high-risk group of the JACLS ALL-02 consisted 
of Induction Therapy (Weeks 1-5),  Early Intensification 
(Weeks 6-9),  Consolidation Therapy A1,  A2,  B1 and 
B2 (Weeks 10-25),  Re-induction Therapy (Weeks 
26-29) and Maintenance Therapy (Weeks 30-108).  
Anti-leukemia agents included in the protocol were 
prednisolone,  dexamethasone,  cyclophosphamide,  
L-asparaginase,  pirarubicin,  vincristine,  methotrexate,  
cytosine arabinoside,  etoposide and 6-mercaptopurine.  
Bone marrow aspiration performed on day 15 of the 
induction phase showed hematological remission,  and 
TCF3-PBX1 was not detected in bone marrow cells by 
PCR.
As a prophylaxis against CNS involvement,  he 
received 3 g/m2 of MTX twice during consolidation 
therapy.  In order to promote MTX clearance and pre-
vent renal impairment,  alkaline hydration at a rate of 
more than 2,500 ml/m2/24 h was initiated with acet-
azolamide prior to MTX infusion and continued until 
the plasma MTX level was sufficiently decreased.  
Moreover,  medicines which can delay MTX clearance,  
such as trimethoprim-sulfamethoxazole (TMP-SMX),  
were withdrawn and avoided.  Each dose of MTX was 
followed by leucovorin (LV) at a dose of 15 mg/m2 
every 6 h from 42 h after the start of the MTX infusion.  
The plasma MTX levels fell to 0.1 µmol/l within 72 h 
after the start of the MTX infusion.  Non-hematological 
adverse events of Common Terminology Criteria for 
Adverse Events (CTCAE) grade 3 or worse were limited 
to abnormal liver function tests.  Although the patient 
had received agents with potential renal toxicities 
(cyclophosphamide: total dose 5,700 mg/m2; metho-
trexate: total dose 6,000 mg/m2) during inpatient treat-
ment,  his creatinine clearance was not impaired 
(166.2 ml/min/1.73 m2) and his renal function was 
normal.
The maintenance therapy was initiated on an outpa-
tient basis with TMP-SMX-based prophylaxis against 
Pneumocystis jiroveci pneumonia.  In week 104 of the 
chemotherapy,  MTX was intravenously administered at 
a dose of 150 mg/m2 together with daily oral 6-mercap-
topurine at a dose of 50 mg/m2.  Before MTX adminis-
tration,  it was confirmed that the patient’s physical 
examination findings and laboratory parameters were 
not remarkable.  The patient visited the hospital 2 days 
later complaining of a poor appetite and vomiting.  He 
had a low-grade fever of 37.3ºC.  He had lost 1 kg of 
weight compared with his last hospital visit,  and his oral 
mucosa was dry.  A diagnostic work-up for gastrointes-
tinal symptoms and fever was performed.  Rapid anti-
gen detection tests for influenza virus,  respiratory syn-
cytial virus and group A Streptococcus were negative.  
Urine,  stool and blood cultures were obtained,  but their 
results turned out to be negative several days later.  
Chest and abdominal X-ray were not remarkable.
Ultrasonography showed significant respiratory 
variation in inferior vena cava diameter.  A blood exam-
ination revealed elevated serum creatinine (Cr),  urea 
nitrogen (UN),  and C-reactive protein (CRP) levels 
(Fig. 1).  A marked reduction in the estimated glomeru-
lar filtration rate (25 ml/min/1.73 m2) was observed 
[11].  A urine test revealed aciduria (pH 5.5) and albu-
minuria (0.3 g/l).  Significant dehydration and the 
development of AKI (CTCAE grade 3) were suspected.
At approximately 48 h after MTX administration,  
the plasma MTX level was 0.73 µmol/l,  which was 
indicative of delayed MTX elimination.  To improve the 
MTX clearance,  a large-volume intravenous fluid infu-
sion and urinary alkalization with sodium bicarbonate 
were initiated.  Moreover,  TMP-SMX was discontinued 
because it could impair MTX clearance.  LV rescue was 
started at a high dose (60 mg/m2) to minimize adverse 
events caused by prolonged MTX exposure [12].  On 
day 6 after MTX administration,  a blood examination 
showed that the plasma MTX concentration had fallen 
below 0.1 µmol/l,  and the Cr,  UN,  and CRP levels had 
improved (Fig. 1).  The patient was transferred to 
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another hospital for further follow-up on day 5 of hos-
pitalization.  Maintenance therapy was discontinued 
because its schedule was close to an end.  Creatinine 
clearance evaluated three months after discharge was 
225.6 ml/min/1.73 m2.
Due to the scarcity of AKI and delayed MTX elimi-
nation after the administration of medium doses of 
MTX,  we analyzed the patient for single nucleotide 
polymorphisms (SNP) of candidate genes associated 
with MTX pharmacokinetics and toxicities.  The candi-
date genes consisted of SLCO1B1,  solute carrier family 
19 member 1 (SLC19A1),  solute carrier family 22 mem-
ber 8 (SLC22A8),  methylene tetrahydrofolate reductase 
(MTHFR),  ATP binding cassette subfamily B member 
1 (ABCB1),  ATP binding cassette subfamily C member 
2 (ABCC2) and AT-rich interaction domain 5B 
(ARID5B) [2 , 5-9 , 13-15].  Genomic DNA was isolated 
from peripheral blood mononuclear cells using a 
QIAamp DNA Blood Mini Kit.  The DNA was amplified 
by PCR with individual primer sets,  and direct 
sequencing was performed to determine the genotype 
of each SNP of the target genes.  The analyzed SNPs and 
the sequences of the primer sets for each SNP are listed 
in Table 1.
The direct sequencing analysis showed that the 
patient was homozygous for the minor allele of the 
SLCO1B1 rs4149056 (Fig. 2A),  which has been proved 
to adversely affect MTX clearance by GWAS [7-9].  He 
was also homozygous for the minor alleles of SLCO1B1 
rs4149081 and rs11045879,  which are in linkage dis-
equilibrium with rs4149056 [7].  In addition,  he carried 
heterozygous minor alleles of MTHFR rs1801133 
(Fig. 2B),  ARID5B rs4948496,  rs4948487 and SLC22A8 
rs4149183 (Table 1).
Discussion
MTX clearance affects the toxicity and efficacy of 
MTX treatment in ALL patients.  Many clinical param-
eters,  including renal function,  the existence of third-
space fluid collection,  urinary pH,  and the concurrent 
use of drugs that inhibit MTX excretion,  are known to 
interfere with MTX excretion,  and hence,  the pharma-
cokinetics of MTX [1 , 16].
The SLCO1B1 gene encodes an organic anion trans-
porter and is known to affect the therapeutic as well as 
the toxic effects of many different drugs [17].  It also 
plays a crucial role in the hepatic uptake and clearance 
of MTX [4].  An in vitro analysis showed that MTX 
uptake was reduced in cells with damaging SLCO1B1 
variants [15].  Recently,  GWAS revealed that 
rs4149056,  a non-synonymous SNP of SLCO1B1 
(T521C),  is associated with decreased MTX clearance.  
Specifically,  it was found that MTX clearance was 
reduced by 13% in patients with the CC genotype com-
pared with that seen in patients with the TT genotype 
[7 , 8].
The patient also carried heterozygous minor alleles 
of MTHFR rs1801133,  ARID5B rs1801133/rs4948487,  
and SLC22A8 rs4149183.  A previous study showed that 
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Day1 Day2 Day3 Day4 Day5 Day6 Day7
MTX(μmol/l) 0.73 0.09
UN(mg/dl) 49.3 10.215.040.7 21.38.8
eGFR(ml/min) 25 826331 47144
Hour 186
Intravenous MTX 150 mg/m2
Urinary alkalyzation
Cr(mg/dl) 1.83 0.560.731.50 0.980.32
CRP(mg/dl) 2.81 1.142.563.00 5.250.2
Leucovorin rescue
0.71 0.22
Fig. 1　 Timeline of the patientʼs renal function indices and serum CRP and MTX concentrations after the administration of MTX.  
The supportive care provided to promote MTX excretion is indicated at the top.  Cr,  serum creatinine; CRP,  serum C-reactive pro-
tein; eGFR,  estimated glomerular filtration rate; MTX,  methotrexate; UN,  serum urea nitrogen.
heterozygous carriers of MTHFR rs1801133 minor 
alleles had higher levels of plasma MTX than homozy-
gous carriers of major alleles [5].  On the other hand,  
heterozygous carriers of minor alleles of ARID5B 
rs1801133/rs4948487 or SLC22A8 rs4149183 did not 
exhibit exacerbated MTX toxicity or decreased MTX 
clearance compared to homozygous carriers of major 
alleles [6].  According to the GWAS,  none of these 
polymorphisms were associated with impaired MTX 
clearance [7].
AKI are not uncommon after the administration of 
MTX at doses exceeding 500 mg/m2.  MTX-induced 
renal toxicity usually results in crystal-induced AKI.  
After the administration of MTX,  most of the drug and 
its metabolites are excreted in urine,  but they can pre-
cipitate within the renal tubules in patients with 
increased urinary concentrations of MTX or acidic urine 
[3 ,16].  In rare cases,  such renal impairment can develop 
after the administration of lower doses of MTX [2].
In the present case,  direct sequencing of the candi-
date genes for delayed MTX clearance revealed that the 
patient was homozygous for dysfunctional alleles of 
SLCO1B1 rs4149056 and heterozygous for a dysfunc-
tional allele of MTHFR rs1801133.  However,  neither 
nephrotoxicity nor delayed MTX elimination was 
observed when higher doses of MTX were adminis-
tered during Consolidation Therapy,  probably because 
renal impairment was prevented by massive hydration 
of more than 2,500 ml/m2/day,  the discontinuation of 
drugs preventing methotrexate elimination such as 
TMP-SMX and urine alkalization with acetazolamide 
and sodium bicarbonate.  This suggests that,  in addition 
to the dysfunctional minor alleles associated with MTX 
toxicities and clearance,  other risk factors,  such as vol-
ume depletion,  acidic urine and the concurrent use of 
drugs that interfere with MTX clearance,  are required 
for renal impairment and delayed MTX elimination.
It is possible that the patient was suffering from gas-
troenteritis of unknown etiology when the intravenous 
MTX was administered and that he subsequently 
became dehydrated because of decreased oral intake due 
to nausea and vomiting.  We speculate that the signifi-
cant decrease in MTX clearance was at least partly due 
to loss-of-function polymorphism in SLCO1B1 
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Table 1　 The list of analyzed polymorphisms of the candidate genes associated with MTX toxicities and plasma levels





SLCO1B1 rs4149056 T521C T/C CC Forward: CAGCCATGAGGAACTATGAGTCCAT
Reverse: AGCCCCAATGGTACTATGGGAGTC
SLCO1B1 rs11045879 intron variant T/C CC Forward: CTGGAGACCACTGTGCTTTTTACTG
Reverse: GCAATTATTGCAAGGTTTCAGGACA 
SLCO1B1 rs4149081 intron variant G/A AA Forward: CTGACTTTGCATGCAGTATGGTATCA 
Reverse: AATTGACATATGACCAGAGCCCC 
MTHFR rs1801133 C677T C/T CT Forward: CAGAAGCATATCAGTCATGAGCCC
Reverse: ATGCCTTCACAAAGCGGAAGAAT
MTHFR rs1801131 A1298C A/C AA Forward: AGTTTGCATGCTTGTGGTTGAC
Reverse: CAGCATCACTCACTTTGTGACCA
SLCO19A1 rs1051266 G80A G/A GG Forward: GACCATCTTCCAAGGTGCCCT
Reverse: GAAGCTCTCCCCTGGCCGTAT
ABCB1 rs1045642 C3435T C/T CC Forward: CTGGTCCTGAAGTTGATCTGTGAAC
Reverse: AAATCAAACTATAGGCCAGAGAGGCTG
ABCC2 rs717620 5ʼ-UTR C/T CC Forward: GGTGACCACCCTAAGTTAACTAACTACCAC
Reverse: TAGTCACATGTCCATCCACTGTTTCA
ARID5B rs4948502 intron variant T/C TT Forward: CCATGTAACTCCAGTTCAGGAAAGC
Reverse: GAGAGTTGTTTCTTAGGCCCACTGA
ARID5B rs4948496 intron variant C/T CT Forward: GCCAGAGAATTGATATCCTCAGAGG
Reverse: ACTTGTTGGTAGGGACTGGAATCAG
ARID5B rs4948487 intron variant C/A CA Forward: CAGCAGTCAACCCATAAAAAGTCAGG
Reverse: CACTAGATGCCACTATGAACAATGGC
SLC22A8 rs4149183 intron variant T/C CT Forward: GAGTCTATGGTGCTACAGGCCTGAT
Reverse: GGTTCAACATGTTGGTAATGAGCTCTC
(rs4149056) and MTHFR (rs1801133),  as well as other 
risk factors such as aciduria,  decrease in urine output 
and the concurrent use of TMP-SMX.  Finally,  AKI may 
have developed due to intratubular crystal formation.
This case suggests that renal function should be 
monitored using the estimated glomerular filtration rate 
and/or creatinine clearance throughout the course of 
chemotherapy that includes MTX,  and investigation of 
SLCO1B1 and MTHFR gene polymorphisms should be 
carried out if any signs indicating kidney impairment or 
delayed MTX clearance are observed.  If any of the gene 
polymorphisms affecting MTX toxicities and clearance 
are positive,  it is prudent to closely monitor the MTX 
concentration and perform renal-protective measures 
such as intravenous hydration even when MTX is 
administered at a medium or low dose.
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